Background/Introduction
=======================

Acute kidney injury (AKI) is a significant complication of cardiac surgery and is associated with increased morbidity and mortality \[[@B1]\]. Despite much research, there is no specific therapy available. Although AKI can be multifactorial, ischaemia reperfusion injury (IRI) often plays a key role. Thus, cardiac surgery offers an attractive opportunity for translational AKI research given the predictive haemodynamic challenge to renal perfusion.

Hemeoxygenase-1 (HO-1) is a key inducible anti-inflammatory enzyme that catalyses the breakdown of the pro-oxidant protein heme ubiquitously found at inflamed sites. The drug heme arginate has been in use for over 20 years in the treatment of porphyria but also upregulates HO-1 in peripheral blood mononuclear cells (PBMCs) \[[@B2]\] and ameliorates calf muscle ischaemia \[[@B3]\]. In addition, treatment of mice with heme arginate prior to renal IRI strongly upregulates renal HO-1 expression and protects from AKI \[[@B4]\]. We therefore hypothesise that HA may offer a prophylactic therapy for human renal IRI via the upregulation of HO-1.

Aims/Objectives
===============

The HACS Trial aims to determine whether heme arginate will upregulate HO-1 in PBMCs in patients aged 60 or above who are scheduled for cardiac surgery, and to verify its safety in this patient cohort.

Method
======

20 participants, who are scheduled for elective cardiac surgery, will be randomised to receive 1 mg/kg or 3 mg/kg heme arginate. The primary end point will be the difference in PBMC HO-1 protein from baseline at 24 hours. Secondary end points include HO-1 gene expression, safety and HO-1 genotype.

Results
=======

Results are expected in July 2015. At the time of abstract submission, 14 of 20 participants have been recruited.

Discussion/Conclusion
=====================

Data from the HACS trial will inform a subsequent multicentre randomised controlled trial of heme arginate versus placebo in the prevention of AKI in patients deemed to be at higher risk of developing AKI post cardiac surgery
